Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated June 28, 2023, reports the completion of the acquisition of BELLUS Health Inc. The transaction was executed via a plan of arrangement approved by BELLUS shareholders on June 16, 2023. The acquisition targets the biopharmaceutical company's lead asset, camlipixant, a Phase III P2X3 antagonist for refractory chronic cough (RCC).
Key Financial Metrics
- Transaction Value: Total equity value of US$2.0 billion (approximately £1.6 billion / C$2.6 billion).
- Consideration: US$14.75 per common share in cash for all outstanding BELLUS shares.
- Premium: Approximately 103% premium to BELLUS' closing stock price on April 17, 2023, and 101% premium to the 30-day volume-weighted average price (VWAP) ending April 17, 2023.
- Revenue and Profit: The filing text does not provide specific revenue, profit, cash flow, or margin figures for GSK or BELLUS for the reporting period.
- Debt and Liquidity: The filing text does not provide specific debt or liquidity metrics.
Material Changes
The primary material change is the full acquisition of BELLUS Health Inc., adding camlipixant to GSK's respiratory portfolio. This expands GSK's pipeline in the treatment of refractory chronic cough, a condition with no currently approved medicines in the US or EU. BELLUS has cancelled its annual shareholder meeting originally scheduled for June 30, 2023, following the closing of the arrangement.
Guidance, Outlook, and Risks
- Outlook: Management expects the acquisition to be accretive to adjusted earnings per share (EPS) from 2027 onwards. Significant sales potential is projected through 2031 and beyond, contingent on regulatory approval and launch.
- Management Commentary: Luke Miels, Chief Commercial Officer, stated the acquisition is highly synergistic with GSK's respiratory expertise and R&D capabilities. The focus is now on progressing camlipixant through Phase III trials.
- Risks: Forward-looking statements are subject to risks including clinical trial outcomes, regulatory approval uncertainties, and factors detailed in GSK's 2022 Form 20-F and Q1 2023 results. Camlipixant is not currently approved anywhere in the world.
Investor Verification Checklist
- Verify the status of the CALM Phase III clinical development programme for camlipixant.
- Confirm the timeline for anticipated regulatory approval and commercial launch.
- Review GSK's 2022 Form 20-F and Q1 2023 results for detailed risk factors and financial context not included in this announcement.
- Monitor the integration of BELLUS' assets into GSK's respiratory portfolio.